Investigational drug · Phase 2
TNO155
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation, KRAS G12C Mutant Solid Tumors.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
10
Any phase or sponsor naming "TNO155"
First trial start
2021
Feb 24, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TNO155", any sponsor or status.
- Phase 110
Conditions studied
As listed on its trial records.
- Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer
- Advanced Solid Tumors Harboring the KRAS G12C Mutation
- KRAS G12C Mutant Solid Tumors
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Colorectal
- Cancer of Lung
- Cancer of the Lung
- Lung Cancer
- Neoplasms, Lung
- Neoplasms, Pulmonary
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "TNO155" as an intervention, largest first.
- Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)Active, not recruiting
AmgenAmgen (AMGN)
NCT04185883 · 610 participants · Start Dec 17, 2019 · Primary completion Dec 17, 2026
Drug: Sotorasib; Trametinib and 14 more · For: Advanced Solid Tumors; Kirsten Rat Sarcoma (KRAS) pG12C Mutation
Sites: Tucson, Arizona; Duarte, California; La Jolla, California · 90 sites in all
- Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT04699188 · 344 participants · Start Feb 24, 2021 · Primary completion Jan 25, 2027
Drug: JDQ443; TNO155 and 1 more · For: KRAS G12C Mutant Solid Tumors; Carcinoma, Non-Small-Cell Lung; Carcinoma, Colorectal and 7 more
Sites: Atlanta, Georgia; Boston, Massachusetts; Pittsburgh, Pennsylvania · 38 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT03114319 · 227 participants · Start May 26, 2017 · Primary completion Jul 4, 2025
Drug: TNO155; TNO155 in combination with EGF816 (nazartinib) · For: Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC); KRAS G12-mutant NSCLC; Esophageal Squamous Cell Cancer (SCC) and 4 more
Sites: Tampa, Florida; Boston, Massachusetts; New York, New York · 18 sites in all
- Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected MalignanciesTerminated
Novartis PharmaceuticalsNovartis (NVS)
NCT04000529 · 122 participants · Start Jul 30, 2019 · Primary completion Jan 15, 2024
Drug: TNO155; Spartalizumab and 1 more · For: Non-small Cell Lung Carcinoma; Head and Neck Squamous Cell Carcinoma; Esophageal SCC and 2 more
Sites: Boston, Massachusetts; Westmead, Australia; Brussels, Belgium · 10 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT04294160 · 122 participants · Start Jul 22, 2020 · Primary completion Sep 25, 2024
Drug: Dabrafenib; LTT462 and 5 more · For: BRAF V600 Colorectal Cancer
Sites: Los Angeles, California; Boston, Massachusetts; Nashville, Tennessee · 18 sites in all
- Lorlatinib Combinations in Lung CancerStatus unknown
Massachusetts General HospitalAcademic, hospital or other
NCT04292119 · 96 participants (planned) · Start May 1, 2020 · Primary completion Dec 1, 2022
Drug: Lorlatinib; Crizotinib and 2 more · For: Lung Cancer; Anaplastic Lymphoma Kinase Gene Translocation; ROS1 Rearrangement and 4 more
Sites: Boston, Massachusetts · 2 sites in all
Mirati Therapeutics Inc.Bristol Myers Squibb (BMY)
NCT04330664 · 86 participants · Start Apr 7, 2020 · Primary completion Jul 29, 2022
Drug: MRTX849; TNO155 · For: Advanced Cancer; Metastatic Cancer; Malignant Neoplastic Disease
Sites: Los Angeles, California; Orange, California; Chicago, Illinois · 17 sites in all
- Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study TreatmentsActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07468071 · 25 participants · Start Jun 8, 2026 · Primary completion Jun 11, 2029
Drug: Opnurasib; TNO155 and 3 more · For: Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer; Advanced Solid Tumors Harboring the KRAS G12C Mutation
Sites: Sint-Niklaas, Belgium; Leuven, Belgium; Montreal, Canada · 21 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT05541159 · 0 participants · Start Mar 19, 2025 · Primary completion Jul 15, 2025
Drug: TNO155 · For: Renal Impairment
Novartis PharmaceuticalsNovartis (NVS)
NCT05490030 · 0 participants · Start Mar 6, 2025 · Primary completion Jun 26, 2025
Drug: TNO155 · For: Hepatic Impairment
Newest research
PubMed records naming it or its code names, newest first.
- TEAD inhibitors synergize with MEK, SHP2 and mTOR inhibitors in NF1 and NF2 cell lines.
Yang Y, Gurunathan S, Schechter S, et al. · MicroPubl Biol 2026
- Combination therapy with lorlatinib and mitogen-activated protein kinase pathway inhibition in previously treated ALK- or ROS1-rearranged lung cancer.
Schneider JL, Muzikansky A, Krueger E, et al. · Lung Cancer 2026
- Allosteric SHP2 inhibitors suppress lung cancer cell migration by inhibiting non-canonical activation of EphA2 via the ERK-RSK signaling pathway.
Nguyen K, Zhou Y, Yokoyama S, et al. · Sci Rep 2025
- RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types.
Davoudi Z, Dexheimer TS, Coussens NP, et al. · Cancer Res Commun 2025
- Computational study on the binding mechanism of allosteric drug TNO155 inhibiting SHP2E76A.
Yang L, Zhao H, Yuan F, et al. · Mol Divers 2025
- Discovery of novel phenyl urea SHP2 inhibitors with anti-colon cancer and potential immunomodulatory effects.
Wang K, Zhang X, Hu Y, et al. · Eur J Med Chem 2025
Also in development for Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer
- JDQ443OpnurasibPhase 23 trials
Novartis · Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation, Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.